Dr. Joseph Rosado, MD, MBA

---

Safety, Dosing, and Quality — From Device Toxicology to Edible Pharmacokinetics A 2026 Clinical Framework for Florida Practitioners

Dr. Joseph Rosado, MD, MBA, JOSEPH ROSADO, MD, LLC

As Florida’s medical cannabis program matures, clinical risk is increasingly driven not by access, but by product complexity, delivery devices, and dosing variability. This session provides Florida practitioners with a practical, evidence-based framework for evaluating the safety, dosing, and quality of inhaled and ingested cannabinoids in 2026. Using real-world Florida case studies, current toxicology data, and updated pharmacokinetic insights, the presentation examines device-related risks in vaporized products, delayed and fast-acting edible formulations, and the clinical significance of Certificates of Analysis (COAs). Attendees will learn how to distinguish product failure from therapeutic failure, counsel patients more effectively based on route of administration, and apply quality signals that meaningfully impact patient safety in a modern medical cannabis program.

Joseph Rosado, MD, MBA is a Florida-based physician with expertise in medical cannabis, clinical risk assessment, and patient-centered cannabinoid therapy. As a Medical Review Officer (MRO), he regularly educates clinicians on the toxicology, pharmacokinetics, and quality considerations associated with modern cannabis delivery systems, focusing on translating emerging science into practical clinical decision-making. Dr. Rosado is a frequent speaker at medical conferences and has been a guest on multiple podcasts focused on evidence-based cannabis medicine, policy, and patient safety.